Eric S Daar Selected Research

efavirenz (Sustiva)

10/2021	Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.
1/2019	Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.
1/2018	Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.
12/2017	Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.
1/2017	Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.
2/2015	Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.
7/2014	Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.
2/2013	Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
12/2012	Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
7/2012	Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric S Daar Research Topics

Disease

33	Infections 12/2021 - 10/2002
27	Acquired Immunodeficiency Syndrome (AIDS) 10/2021 - 11/2005
13	HIV Infections (HIV Infection) 01/2018 - 08/2002
9	Viremia 01/2016 - 01/2005
6	Disease Progression 12/2021 - 08/2005
6	Inflammation (Inflammations) 01/2019 - 08/2005
5	COVID-19 01/2022 - 09/2021
3	Substance-Related Disorders (Drug Abuse) 10/2021 - 04/2008
3	Insulin Resistance 01/2019 - 04/2010
3	Brain Injuries (Brain Injury) 01/2019 - 01/2013
3	Persistent Infection 07/2014 - 05/2005
2	AIDS Dementia Complex 01/2019 - 01/2013
2	Coinfection 07/2017 - 01/2016
2	Virus Diseases (Viral Diseases) 01/2015 - 12/2010
2	Hyperbilirubinemia 04/2014 - 02/2013
2	Cognitive Dysfunction 01/2013 - 08/2011
2	Body Weight (Weight, Body) 12/2007 - 04/2004
2	Superinfection 11/2006 - 01/2005
2	Drug-Related Side Effects and Adverse Reactions 09/2004 - 08/2004
1	Weight Gain 10/2021
1	Headache (Headaches) 01/2018
1	Nausea 11/2017
1	Hepatitis B 11/2017
1	Fibrosis (Cirrhosis) 07/2017
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2015
1	Proteinuria 09/2014
1	Albuminuria 09/2014
1	Chronic Renal Insufficiency 03/2014
1	Neuralgia (Stump Neuralgia) 07/2013

Drug/Important Bio-Agent (IBA)

20	RNA (Ribonucleic Acid)IBA 12/2021 - 06/2005
14	efavirenz (Sustiva)FDA Link 10/2021 - 12/2007
12	Tenofovir (Viread)FDA Link 10/2021 - 12/2009
12	Emtricitabine (Emtriva)FDA Link 01/2019 - 12/2009
10	Ritonavir (Norvir)FDA Link 01/2019 - 03/2004
10	Atazanavir Sulfate (Reyataz)FDA Link 01/2019 - 12/2009
8	lamivudine drug combination abacavir FDA Link 01/2019 - 12/2009
7	VaccinesIBA 12/2021 - 01/2005
7	Pharmaceutical PreparationsIBA 01/2018 - 08/2002
5	Protease Inhibitors (Protease Inhibitor)IBA 01/2019 - 03/2004
5	Reverse Transcriptase InhibitorsIBA 01/2018 - 04/2008
5	EpitopesIBA 01/2018 - 01/2005
4	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 10/2002
3	Monoclonal AntibodiesIBA 01/2022 - 12/2021
3	abacavir (Ziagen)FDA Link 10/2021 - 02/2015
3	tenofovir alafenamideIBA 01/2018 - 04/2016
3	NucleosidesIBA 01/2018 - 04/2008
3	Biomarkers (Surrogate Marker)IBA 06/2015 - 02/2014
3	RacivirIBA 09/2014 - 10/2011
3	Peptide Hydrolases (Proteases)FDA Link 12/2012 - 04/2008
3	Amino Acids FDA Link 12/2012 - 03/2004
2	Antiviral Agents (Antivirals)IBA 12/2021 - 09/2021
2	bamlanivimabIBA 12/2021 - 09/2021
2	AntigensIBA 12/2021 - 01/2008
2	Cytochrome P-450 CYP2B6 (CYP2B6)IBA 10/2021 - 12/2012
2	Mitochondrial DNA (mtDNA)IBA 01/2019 - 02/2013
2	bictegravirIBA 01/2018 - 11/2017
2	HLA-B Antigens (HLA-B)IBA 11/2017 - 08/2005
2	CytokinesIBA 01/2016 - 08/2005
2	CreatinineIBA 09/2015 - 03/2014
2	Cystatin CIBA 06/2015 - 03/2014
2	NucleotidesIBA 09/2014 - 10/2013
2	Proteins (Proteins, Gene)FDA Link 07/2014 - 12/2010
2	Methamphetamine (Desoxyn)FDA LinkGeneric 04/2008 - 11/2006
2	EnzymesIBA 01/2008 - 08/2005
1	Nucleic AcidsIBA 12/2021
1	ChAdOx1 nCoV-19IBA 12/2021
1	Integrase InhibitorsIBA 10/2021
1	IntegrasesIBA 10/2021
1	theasinensin AIBA 01/2021
1	Anti-Retroviral Agents (Antiretroviral Agents)IBA 01/2020
1	Capsid Proteins (Capsid Protein)IBA 01/2020
1	Methotrexate (Mexate)FDA LinkGeneric 01/2019
1	AdiponectinIBA 01/2019
1	TabletsIBA 01/2018
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2018
1	Lamivudine (Epivir)FDA Link 11/2017
1	dolutegravirIBA 11/2017
1	dimemorfan (AT 17)IBA 07/2017
1	Messenger RNA (mRNA)IBA 01/2016
1	ChemokinesIBA 01/2016
1	Protons (Proton)IBA 05/2015
1	Lipopolysaccharide ReceptorsIBA 05/2015
1	Biological FactorsIBA 01/2015
1	Histocompatibility Antigens Class IIBA 07/2014
1	Insulin (Novolin)FDA Link 06/2014
1	Glucose (Dextrose)FDA LinkGeneric 06/2014
1	Hemoglobins (Hemoglobin)IBA 04/2014
1	BilirubinIBA 04/2014
1	C-Reactive ProteinIBA 02/2014
1	Cell Adhesion MoleculesIBA 02/2014
1	Interleukin-6 (Interleukin 6)IBA 02/2014
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2014
1	Analgesics (Analgesic Drugs)IBA 07/2013

Therapy/Procedure

35	Therapeutics 12/2021 - 04/2004
5	Art Therapy 01/2021 - 07/2014
4	Highly Active Antiretroviral Therapy (HAART) 05/2015 - 04/2004
3	Drug Therapy (Chemotherapy) 01/2018 - 01/2005
2	Renal Dialysis (Hemodialysis) 05/2007 - 08/2005
1	Patient Readmission 01/2019
1	Immunotherapy 07/2014